Reasons to
subscribe
on Hubb
Unified Worldwide Network
in Your Language
Unlimited Ads for FREE
First Page on Search Engines
under HUBB for FREE
Choose Your Own Keywords
for FREE
Multiple Service Apps for FREE
No Commission or Hidden Fees
Direct Contact with Customers
without Agents
Ability to Have Your Own Website
under HUBB for FREE
Expand Your Business
Overseas for FREE
Register now
Promote 57 views
icon-applicant-user
Contact person: Sinopharm
+861082287727 info@sinopharm.com sinopharm.com/
Service category: Manufacturing & Production, Healthcare
Payment:

Description

China National Pharmaceutical Group Co., Ltd. (Sinopharm) is a large healthcare group directly under the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, with 128,000 employees and a full chain in the industry covering R&D, manufacturing, logistics and distribution, retail chains, healthcare, engineering services, exhibitions and conferences, international business and financial services.
Sinopharm owns over 1,100 subsidiaries and 6 listed companies which are Sinopharm Group Co., Ltd. (Sinopharm Holding), China National Medicines Corporation Ltd., China National Accord Medicines Corporation Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd., and China Traditional Chinese Medicine Holdings Co., Ltd.
The past years witnessed Sinopharm’s steady and sound development. From 2009to 2018, the CAGR of revenue and total assets reached 24.24% and 30.54% respectively. Sinopharm ranked 169th in Fortune Global 500 and the revenue of 2018 amounted to nearly 400 billion yuan..
Sinopharm has built a nationwide logistic and distributing network for drugs and medical devices and equipment, including 5logistic hubs, more than 40 provincial-level centers and over 240 municipal-level logistic sites. By establishing the smart medical service system, Sinopharmdelivers quality servicesto more than 230,000 corporate clients.
Sinopharm has an applied pharmaceutical research institute and an engineering design institute, both taking a leading position in China. Two Academicians of Chinese Academy of Engineering, 11 national R&D institutes, 44 provincial-level technology centers and over 5,000 scientists have made remarkable achievements.Sinopharm also chaired in setting over 530 national technical criteria, among which the EV71 vaccine, a first category new drug of China with Sinopharm holding complete independent intellectual property right, reduces the morbidity of hand-foot-and mouth disease among Chinese children. The R&D and launch of sIPV ensures the progress of the national immunization program for polio.

Promotions and offers

icon-applicant-user
Contact person: Sinopharm
+861082287727 info@sinopharm.com
TOP
All the services you need on one platform
Ordering Services Online
All the services you need on one platform
Ordering Services Online

New Services

Coming soon

Show all
Close
Login on Hubb
Reset password